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Abstract: Antimicrobial stewardship is the 
organized and systematic way of educating and 
enforcing evidence-based prescribing of 
antimicrobial agents to control misuse and overuse 
of antibiotics with the aim of curbing antimicrobial 
resistance. There is need to initiate antimicrobial 
stewardship program at various levels in the health 
sector such as health facilities or hospitals in order to 
safeguard and sustain the current antimicrobial 
agents in use. In addition, oxazolidinones are potent 
drugs in management of multidrug resistance 
(MDR) related infections and linezolid is already on 
the market and being considered as a drug of 'last 
resort' for the treatment of MDR bacterial 
infections. Therefore, to avert the development and 
rapid spread of drug resistance against linezolid and 
other oxazolidinone drugs, antimicrobial 
stewardship program needs to be established for 
critical monitoring and regulation of their use at all 
critical levels in the health system hierarchy, 
especially in resource limited countries. 
INTRODUCTION
The rising global burden of infectious diseases is 
worrisome. This had prompted the implementation 
of disease surveillance programs among World 
Health Organization (WHO) Regional Office for 
Africa (AFRO) member states, with the effort to 
improve on the detection, communication to the 
next level of authority, management/treatment and 
1control of disease dissemination . Surveillance is 
defined as the 'ongoing systematic collection, 
collation, analysis and interpretation of data and the 
dissemination of information to those who need to 
1,2know in order that action may be taken’ . 
Surveillance is an important system to use when 
planning, implementing and/or evaluating public 
health practices. Therefore, in 1998 WHO/AFRO 
began to promote the Integrated Disease 
Surveillance and Response (IDSR) to strengthen 
1national disease surveillance system . Through this 
surveillance program, diseases such as cholera, viral 
hemorrhagic fevers, malaria, severe acute 
respiratory illness, diarrheal diseases, HIV/AIDS 
and tuberculosis were classified as public health 
2priorities . The effective monitoring of disease 
trends at any level of health system and effective 
communication within the health level hierarchy 
system is cardinal for proper management and 
prevention of infectious outbreak. Hence, the 
adoption and utilization of IDSR system may aid in 
mounting a rapid detection and response structure to 
any disease outbreaks besides the above cited ones.
Zambia adopted the IDSR in the year 2000 to 
monitor, prevent and control priority notifiable 
infectious diseases in the country, and Zambia 
public health system through the Ministry of Health 
developed and operationalised the IDSR 
implementation structure which starts from the 
3community level up to the national level . To 
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improve the detection of notifiable infectious 
diseases such as Acute Flaccid Paralysis (AFP), 
Measles, Neonatal Tetanus, Dysentery, Cholera, 
Plague, Rabies, Typhoid Fever, Yellow Fever, 
Tuberculosis (TB) and Human In?uenza, the IDSR 
complements the Health Management Information 
System in immediately communicating detected/ 
suspected and/or confirmed reports of any notifiable 
infectious disease to the next level in the reporting 
4chain . However, the rate of laboratory integration is 
quite low in Zambia as observed from the summary 
report of priority diseases, condition and events for 
5weeks 1 – 50, 2018 (Table 1; ).  
Table 1: Extracted summary report of priority 
5diseases for weeks 1 – 50, 2018  
Since IDSR system aims mostly at strengthening 
district level surveillance and response for priority 
diseases, integrating laboratory with laboratory 
support, reducing duplication in reporting, sharing 
resources among disease control programs, and 
translating surveillance and laboratory data into 
2specific and timely public health actions ; the 
laboratory work in this whole process is so valuable 
in confirming the disease etiological agents and 
possible antimicrobial susceptibility. The latter is so 
fundamental in supporting the choice of potent 
antimicrobial agents and to avoid irrational 
antimicrobial use, and minimize resistance 
development. All these can be achieved once 
antimicrobial stewardship programs are established 
and integrated in surveillance programs at a hospital 
level. Therefore, this review discusses antimicrobial 
stewardship in relation with antimicrobial 
resistance, and its benefits in averting oxazolidinone 
resistance in resource limited countries like Zambia.
Antimicrobial Stewardship
The evolutionary rate of antimicrobial resistance 
(AMR) to commonly used antimicrobial agents in 
health systems is alarming. Research scientists in 
association with various stakeholders are working 
tirelessly in finding the undying solution to this 
problem. As the search for effective antimicrobial 
agents is ongoing, various levels 
in the health sector such as 
health facilities or hospitals, 
need to be actively involved in 
safeguarding and sustaining the 
current antimicrobial agents in 
use. This can be achieved 
t h r o u g h  i n i t i a t i n g  a n  
antimicrobial stewardship 
program (ASP). As IDSR 
system is being implemented, 
ASP can also work concurrently 
by monitoring and regulating 
the correct/confirmed use of 
antimicrobial agents. According to the Infectious 
Disease Society of America, antimicrobial 
stewardship is defined as the rational, systematic 
approach to the use of antimicrobial agents in order 
6to achieve optimal outcomes . ASP is a promising 
program to curb irrational use of antimicrobial 
agents and to safeguard the community from AMR 
outbreaks. For instance, Gaffin (2015) reported the 
abuse of ceftriaxone and how this problem was 
7curbed through the formidable ASP team . This 
report further stated the challenges faced in 
implementing a radical decision of reducing the use 
ceftriaxone especially in Clostridium difficile 
 Disease  cumulative week 1 -  50  Cases suspected
 
Cases 
tested
 
Cases 
confirmed
 
Number of 
deaths
Case testing 
rate %
Cholera
 
5  945  2  087  944  113  35.1Meningitis (Neisseria)
 
188  0  0  0  0Measles
 
543  298  19  5  54.8Dysentery
 
45 277
 
3
 
379
 
309
 
0
 
7.5
Typhoid fever
 
692
 
363
 
57
 
0
 
52.5
Yellow fever
 
7
 
0
 
0
 
0
 
0
Anthrax 10 0 0 0 0
Non-bloody 
diarrhoea
262 912 924 101 0 0.4
Schistosomiasis 
(Bilharzia)
16 903 2 580 843 0 15.3
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infections. Therefore. It is imperative that hospitals 
should establish and adhere to the ASP for effective 
8curtailing of AMR . The formed ASP team in various 
hospitals will have an enormous role to play and 
may receive a lot of objections from prescribing 
clinicians but ASP teams may provide guidelines for 
antimicrobial use, educate clinicians regarding 
preferred antimicrobial therapy and provide reports 
on the trends of antimicrobial use versus patient 
9management or resistance . Lessons on developing 
an ASP can be drawn from countries that are using 
the program. Skodvin et al. studied factors that 
influenced doctors' antimicrobial prescribing 
10practices in Norwegian hospitals . The authors 
revealed contextual factors such as a common work 
practice for seeking collegial advice, logistics of 
microbiology test results, and formal leadership and 
systematic training on prudence, that should be 
considered when developing antimicrobial 
10stewardship programs in Norway . These factors 
are also applicable to the Zambian health system. 
For instance, a cordial consultational relationship 
between junior/intern doctors and senior/ 
specialized doctors when prescribing drugs must be 
encouraged at all levels in the health sector. Further 
evidence based antibiotic prescription among 
clinicians should be encouraged when treating 
bacterial infections and microbiology laboratory 
testing logistics should be supported by hospital 
managements. Restoring microbiology laboratory 
operation may promote evidence based treatment 
and management of microbial infections. Thus, 
hospital laboratories being the custodian of 
antibiotic resistance profile data for instance, should 
periodically update clinicians on the status of AMR 
and the potency of currently utilized empiric 
antimicrobial therapy through antibiogram study 
reports.
Oxazolidinones
Over decades ago, infections due to Gram positive 
pathogens were hit with widespread resistance to 
commonly prescribed antibiotics. By then 
vancomycin was a last therapeutic option for 
infection due to methicillin resistant Staphylococcus 
aureus but vancomycin resistant Enterococci had no 
known alternatives while penicillin resistant 
11pneumococci were on the rise . Fortunately, 
oxazolidinones were efficacious against Gram 
positive pathogens and two Food and Drug 
Administration (FDA)-approved oxazolidinones 
were linezolid (released in 2000) and tedizolid 
12(released in 2014) .
Oxazolidinones are novel synthetic bacteriostatic 
class of antibiotics that inhibit protein synthesis by 
preventing formation of the ribosomal-N-
formylmethionyl-tRNA initiation complex through 
binding to the P site of the 50S ribosome . They are 
effective against a wide range of Gram-positive 
bacteria, including methicillin resistance 
Staphylococci, vancomycin resistant Staphylococci, 
vancomycin resistant Enterococci, penicillin 
resistant pneumococci and anaerobes; and the use of 
linezolid, has already been effected in hospitals for 
treatment of Gram positive infections and multidrug 
12, 13resistance tuberculosis complex .
Among the Staphylococcus species, S. aureus, S. 
epidermidis and S. saprophiticus are associated with 
hospital acquired nosocomial infections, indwelling 
medical device linked infections and urinary tract 
14infections especially in girls, respectively . 
Moreover, only S. aureus and S. intermedius are 
coagulase positive bacteria while all other 
Staphylococcus species are coagulase negative 
14bacteria .  S. aureus can cause various forms of 
human infections such as osteomyelitis, meningitis, 
septic arthritis, food borne gastroenteritis, brain 
14,15abscesses, cellulitis and toxic shock syndrome . 
Moreover, S. aureus is a Gram positive normal 
microbiota that colonizes the nasal cavity and 
15,16axillae . However, the bacterium is able to express 
several virulence factors that aid in colonizing host 
tissues, inhibiting phagocytosis and secreting of 
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toxins leading to host tissue damage .  Also, the 
bacterium has the ability to develop resistance to 
several antimicrobial agents which causes 
management of its infections of greater concern. 
Multiple drug resistance (MDR) keeps on rising in S. 
aureus, where methicillin resistance indicates 
multiple resistance and methicillin resistance 
Staphylococcus aureus (MRSA) is the common 
14,17cause of infection outbreak in hospital settings . 
Vancomycin has been an alternative therapeutic 
11drug for MRSA infections , but due to the 
development of resistance, co-trimoxazole 
(trimethoprim/sulfamethoxazole) was revealed as 
an alternative drug to vancomycin in MRSA 
18,19infections . In addition, a plethora of information 
reveals that linezolid and tendizolid are effective 
against MRSA and other Gram positive pathogens. 
20For instance, a randomized study by Harbarth et al.,   
compared a 5-day combination therapy of co-
trimoxazole (160mg trimethoprim and 800mg 
Sulfamethoxazole) thrice a day with 600mg 
rifampicin once daily versus a 7-day therapy of 
600mg linezolid twice daily on MRSA infections. 
They found comparable results between the two 
groups and suggested that a combination of co-
trimoxazole and rifampicin to offer substantial cost 
advantages over linezolid. In addition, a meta-
analysis that compared the activities of vancomycin 
versus linezolid in MRSA infection showed 
21linezolid to be more efficacious than vancomycin . 
Tedizolid, another FDA approved drug is effective 
against Gram positive pathogens. A randomized 
study conducted in japan by Mikamo et al, evaluated 
the efficacy, safety and pharmacokinetics of 
tedizolid versus linezolid in patients with skin and 
22soft tissue infections . The study suggested 
tedizolid phosphate as a better option than linezolid 
even though both drug were well tolerated. In 
23addition, Hall et al.   also pointed out shorter 
duration therapy and increased tolerability of 
tedizolid as being advantageous over linezolid in 
MRSA infections. In spite of some differences 
14,15
between linezolid and tedizolid, the studies reveal 
that oxazolidinone drugs are still effective and may 
be used as drugs of last resort in MRSA and other 
Gram positive infections. Due to the efficacious 
results of oxazolidinones on skin infections, 
pneumonia, central nervous system and 
24,26osteoarticular infection in adults and pediatrics , 
protecting these drugs from abuse to avoid or 
minimize resistance acquisition is of paramount 
importance.    
Besides the widely studied methicillin and 
vancomycin resistance genes, S. aureus has 
acquired the cfr (chloramphenicol/florfenicol 
resistance) gene which confers resistance to the 
phenicols, lincosamides, oxazolidinones, 
pleuromutilins, and streptogramin A, and S. 
epidermidis had been reported as the reservoir of cfr 
17, 27gene . Therefore, with overwhelming reports on 
the presence of cfr gene in clinical, environmental 
16, 17, 18and livestock bacteria species , the repercussion 
of having cfr gene in clinical isolates should be of 
great concern because the gene is easily transferable 
between strains and species. 
Antimicrobial Stewardship and Oxazolidinone 
use
Due to the current key changes to the MDR and 
rifampicin resistance (RR) tuberculosis complex 
treatment regimen, linezolid is among the newly 
introduced drug for management of these 
29infections . So, what does this mean for HIV/TB 
endemic countries like Zambia?
First the information about the prevalence of drug 
resistance among Staphylococci, prevalence of S. 
epidermidis amongst clinical isolates, and the 
prevalence of cfr  gene among clinical  
Staphylococcus species isolates is poorly 
documented. Until we understand the status quo on 
these issues, we cannot be certain that Zambia is not 
affected. 
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Zambia has been experiencing an increase in the 
number of MDR/RR-tuberculosis complex in 
various regions and there are unconfirmed presence 
30of pre-extended drug resistance (XDR) strains . 
According to the recent global tuberculosis report 
by WHO (2018), there are high prevalence of MDR-
TB and XDR-TB cases in the southern region of  
30Africa (Table 2, ). These case strains may possibly 
spread to Zambia due to its land linked status and 
cause an escalation in the level of MDR/RR-TB 
cases. This entails that the utilization rate of 
linezolid may rapidly increase once introduced in 
treatment regimen following WHO rapid 
29communication guidelines . Even though an 
increased prescription of a drug does not necessarily 
translate into resistance acquisition, proper 
regulation of linezolid in this case will be required in 
our country. Owing to the fact that the 
oxazolidinone drugs are considered the last option 
in the management of penicillin-, methicillin- and 
12, 13, 17vancomycin-resistant Gram positive bacteria , 
strong emphasis on its proper use (restricting it to 
MDR/RR-TB and XDR-TB) will be needed to 
prevent early development of resistance. While 
Wasserman et al.'s findings detected linezolid 
resistance in some studied South African MDR-TB 
30patients , proper stewardship of the drug needs to be 
adhered to. Otherwise, infections due to MDR-TB 
and other MDR-Gram positive infectious agents 
may become incurable. Thus, ASP if properly 
established and welcomed by all, can help in 
achieving this purpose.
Table 2: Prevalence of MDR/RR-TB and XDR-
30TB cases in Southern part of Africa
aIncidence rate per 100 000 population; MDR: Multi-drug 
resistance; RR: Rifampicin resistance; XDR: extended 
drug resistance; TB: Tuberculosis
Conclusion and future prospective
Oxazolidinones are powerful drugs in management 
of MDR infections and linezolid is already on the 
market for that effect. To avoid development and 
rapid spread of drug resistance against linezolid and 
other oxazolidinone drugs, it is cardinal to constitute 
an ASP team to spearhead infection prevention/ 
control and antibiotic use programs at a hospital. The 
team should fortify antimicrobial stewardship 
program for critical monitoring and regulation of 
oxazolidinone use. This can be achieved by 
obtaining guidance from the ASP team or an 
infectious disease consulting physician coupling 
with microbiological documentation before 
25, 32prescribing the drug  as this strategy has been 
tested in other hospitals  and found to be helpful. 
Secondly, studies to ascertain the prevalence levels 
of cfr gene amongst Staphylococcus strains will help 
in projecting the resistance levels that may be 
associated with linezolid and/or other oxazolidinone 
drugs in Zambia. Therefore, to avoid drug resistance 
development to oxazolidonine and of course any 
other drug, antimicrobial stewardship is a promising 
program to curb the scourge of antimicrobial 
resistance and its support and implementation 
should begin from the point of care up to the 
ministerial level. Thus, a multisectoral approach is 
required to curb drug resistance in Zambia and other 
resource limited countries in order to have and 
sustain an effective low cost health system. 
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